Alamar Biosciences, Inc. (NASDAQ: ALMR) is a Healthcare company (Biotechnology) with a market capitalization of $2.1B. The Maz Rating grades it against the other companies in its sector.
Alamar Biosciences, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $30.64, Alamar Biosciences, Inc. trades at 18.5x sales and 6.9x book value. Over the last twelve months it generated about $115M of revenue and a net loss of $58M. It runs a gross margin of 59.3%, an operating margin of -42.1% and a net margin of -48.2%. It shows return on equity of -78.7%, return on invested capital of -13.8% and a free cash flow yield of -3.2%. On the balance sheet: a debt-to-equity ratio of 0.14 and a current ratio of 9.49. Over the past 52 weeks the share price ranged from $18.85 to $39.61, with a beta of -6.18.
Alamar Biosciences, Inc. does not currently pay a dividend.
3 Wall Street analyst ratings cover the stock: 3 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Alamar Biosciences operates as a commercial-stage proteomics firm, specializing in the highly sensitive, simultaneous identification of various proteins for both scientific research and prospective medical applications. Their integrated platform brings together proprietary instruments, specialized consumables, and unique software, forming a comprehensive, end-to-end solution. This system is designed for accurately quantifying multiple proteins, particularly those present in low concentrations, across a wide array of research and potential clinical uses.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Alamar Biosciences, Inc. (ALMR) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 12.2% / 30% · Interest income / Revenue 6.92% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 12.2% / 33% · Receivables / Mkt Cap (36m) 1.16% / 49% · Interest income / Revenue 6.92% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 12.2% / 33.33% · Receivables / Mkt Cap (24m) 1.16% / 33.33% · Interest income / Revenue 6.92% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 30.5% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 52.1% / 33.33% · Receivables / Avg Assets (4Q) 6.78% / 33.33% · Interest income / Revenue 6.92% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 59.9% / 33.33% · (Cash+Recv) / Total Assets 65.7% / 33.33% · Interest income / Revenue 6.92% / 5% | Fail |
No. As of September 2026, Alamar Biosciences, Inc. (ALMR) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Alamar Biosciences, Inc. is over the AAOIFI limit on Interest income / Revenue.
About 6.92% of each dividend: Alamar Biosciences, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.